Saudi-Pakistan Investment Forum discusses boosting trade and investment partnerships    Crown Prince concludes MEGISummit: We will work seriously to achieve our goals    EXIM Bank signs MoU with Japanese Sumitomo Mitsui Banking Corporation    Saudi Pavilion at EXPO 2020 marks 76th anniversary of UN establishment    Greece premier praises importance of Middle East Green Initiative Summit    Saudi Arabia calls for restraint, de-escalation in Sudan    Riyadh Season hosts Barcelona and Boca Juniors on Maradona Cup night    Monshaat partners with MITEF Saudi & Arab Startup Competition    HSBC CEO — 2021 set to be first trillion-dollar year for green bonds    Riyadh dominates GCC rankings in human capital    All eyes on Jeddah! World's best golfers set for climax of Aramco Team Series    Crown Prince launches series of regional initiatives for climate action at MEGI Summit Ushering in a new green era for Mideast region    WFP's Beasley lauds Saudi Arabia's role in providing aid to millions around the globe    RedSeaIFF announces best short films by emerging Saudi filmmakers 15 shorts make up New Saudi/New Cinema slate    Pakistan hammer India by 10 wickets to clinch T20 win    Michael Jordan's trainers sell for record $1.47m at auction    China postpones Beijing marathon due to Covid surge    US actor James Michael Tyler dies aged 59    Bride's fingerprint not required in revised e-marriage contract    'Easy On Me': Adele returns to UK number one    'Be a Star' — WWE stars fight cyberbullying in Riyadh    Bollywood superstar's son denied bail in drugs case    Saudis, expats mourn death of prominent Filipino preacher in Riyadh    Bollywood actor Sidharth Shukla dies at 40    Custodian of the Two Holy Mosques Directs KSrelief to Urgently Provide Malaysia with Medical, Preventive Equipment and Supplies to Address COVID-19 Pandemic    Custodian of the Two Holy Mosques Congratulates President of Maldives on Independence Day    Weather Forecast for Sunday    RSNF Commander Patronizes Ceremonial Launching of His Majesty's Ship "Jazan"    OIC Condemns Houthi Attempts to Target Civilians in Saudi Arabia    Philippines evacuates thousands as monsoon rains flood cities, provinces    Heavy rain in India triggers floods, landslides; at least 125 dead    U.S. Records 64,321 New Infections of Coronavirus    Without Fans, Tokyo Olympics Kicked Off    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Dr. Mohammed Sulaiman Al-Jasser, Saudi Arabia's Pick to Chair IsDB Group for the next five years, unanimously approved by BoG Committee of Procedures    Saudi Press: Fitch affirms Saudi Credit Rating at "A" with a revised outlook to stable from negative    Handled Cargo at Saudi Ports Increases during June 2021    SDAIA, DARP & STC Launch Pilgrim's Smart Bracelet (NUSK)    2 Goals by Diaz Gives Colombia 3rd Place at Copa America    Saudi Cinema Night at Arab World Institute in Paris Kicks Off    KSU Leads Joint International Scientific Project for Early Detection of Breast Cancer    Saudi Arabia to Participate in Cannes Film Festival 2021    Arab Cup U-17 Championship Draw Saudi Arabia, Morocco, Palestine, Kuwait, in the 1st Group    AWI Hosts Saudi Cinema Nights in Paris    Brazil Beats Chile at Copa America Despite 2nd-Half Red Card    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Russia's Sputnik V vaccine 91.6% effective in late-stage trial
Published in The Saudi Gazette on 02 - 02 - 2021

After criticism last year for an early rollout, Russia's Sputnik V vaccine is 91.6 percent effective against symptomatic COVID-19 and 100 percent effective against severe and moderate disease, according to an interim analysis of the vaccine's Phase 3 trial results.
The preliminary findings were published in The Lancet on Tuesday and are based on data gathered from 19,866 participants, of which around three-quarters (14,964) received two doses of the vaccine and a quarter (4,902) were given a placebo.
Sixteen cases of symptomatic COVID-19 were confirmed in the vaccine group 21 days after participants received the first vaccine dose. Sixty two cases were found in the placebo group — equating to an efficacy of 91.6 percent.
The trial included 2,144 people over the age of 60 and a sub-analysis conducted on this group revealed the vaccine was well tolerated and had a similar efficacy of 91.8 percent.
The team also analyzed the efficacy of the vaccine against severe and moderate COVID-19 disease and 21 days after the first dose no severe or moderate cases were reported in the vaccinated group, while 20 were reported in the placebo group.
Serious adverse events associated with vaccination were also rare —less than 0.2 percent in people who received the vaccine. The majority of side-effects that were reported were mild side, such as pain at the injection site, flu like symptoms and low energy levels, according to the study.
The analysis includes only symptomatic cases of COVID-19, however, and the authors note more research is needed to understand the vaccine's efficacy against asymptomatic COVID-19-19, transmission and how long protection may last.
The majority of participants in the trial were also white so further research is needed to confirm the results across other ethic groups. The trial is also ongoing and is aiming to include a total of 40,000 participants.
Dr. Inna V Dolzhikova, co-lead author of the study, said the analysis suggested the vaccine had "high efficacy, immunogenicity, and a good tolerability profile in participants aged 18 years or older."
Dolzhikova works at Russia's Gamaleya National Research Centre for Epidemiology and Microbiology, which developed the vaccine.
The people in the trial were given PCR Covid-19 tests when they received the second shot. They took a further test if they reported symptoms of respiratory infection.
The Sputnik V vaccine is a two-dose adenoviral vector vaccine using two different adenoviruses for each dose, with doses administered 21 days apart. With this type of vaccine, an adenovirus is altered so that it can deliver a piece of genetic material from the virus that causes COVID-19 into the body and get cells to express the spike induce found on the virus and induce an immune response. It's an approach similar to the vaccines developed by AstraZeneca and Johnson & Johnson.
The authors say that using a different adenovirus vector for the booster vaccination may help create a more powerful immune response.
One advantage of adenoviral vaccines is that they do not need to be stored and transported in extremely cold temperatures, scientists say. Sputnik V only needs to be refrigerated and costs $10 per dose, according to Russian Direct Investment Fund, which funded vaccine production and is responsible for selling it globally.
"This is a useful addition to the published data on COVID-19 vaccine effectiveness," Dr. Julian Tang, clinical virologist at the University of Leicester.
But he highlighted that "median follow up was 48 days from the first dose, so the study cannot assess the full duration of protection."
The vaccine's production has been funded by the Russian Direct Investment Fund (RDIF), which is also responsible for selling it globally.
The vaccine is already approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Guinea, Tunisia, Armenia and the Palestinian territories. Sputnik V has so far been administered to more than 2 million people worldwide.
Russia drew criticism from scientific circles last year when it approved Sputnik V for public use in August — before the crucial Phase 3 trials had been completed.
"Despite the earlier misgivings about the way this Russian Sputnik V vaccine was rolled out more widely — ahead of sufficient Phase 3 trial data — this approach has been justified to some extent now," Tang said.
"The vaccine trial results are coming thick and fast as high infection rates in areas where Phase 3 clinical trials provide increasing amounts of data that together encourages us to believe that vaccines will soon be able to drive down the human cost of Covid-19," added Alexander Edwards, associate professor in Biomedical Technology at the Reading School of Pharmacy, University of Reading.
"Manufacturing may remain a bottleneck for months to come, so the more vaccines available, the better for global health," he said. — Courtesy CNN


Clic here to read the story from its source.